TQ Course | Interpretation and Utilization of New and Old Technologies (Pittsburgh 2023) by Innereactive | Feb 14, 2023 | 2023 Pittsburgh, TQ Courses | 0 comments "*" indicates required fields HiddenInterpretation and Utilization of New and Old TechnologiesHiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. How large is the diameter of the macula?* A. 0.35 mm B. 1.5 mm C. 2.5 mm D. 5.5 mm 2. The Beckman Committee Classification of AMD – based on presence of lesions within _____ of fovea in either eye.* A. 1 DD B. 2 DD C. 5 DD D. 10 DD 3. Using the Beckman Committee Classification of AMD. If a patient has none or a few small drusen with no AMD pigmentary abnormalities. The patient is classified as:* A. No AMD B. Early AMD C. Intermediate AMD D. Advanced AMD 4. Using the Beckman Committee Classification of AMD. If a patient has 1 large drusen and any AMD pigmentary changes. The patient is classified as:* A. No AMD B. Early AMD C. Intermediate AMD D. Advanced AMD 5. Which instrument is able to detect the sub-clinical or sub-structural – cholesterol layer in AMD?* A. Spectral domain OCT B. OCT Angiography C. Sodium Fluorescein Angiography D. Dark adaptation 6. Type I choroidal neovascularization is considered:* A. Occult B. Classic C. RAP D. Mixed 7. Type III choroidal neovascularization is considered:* A. Occult B. Classic C. RAP D. Mixed 8. Which instrument is able to detect a subclinical CNV or “Occult non-exudative CNV”?* A. Spectral domain OCT B scan B. OCT Angiography C. Sodium Fluorescein Angiography D. Dark adaptation 9. When a subclinical CNV or “Occult non-exudative CNV” is found in an eye, Risk of exudation at 12 months is ____ times greater compared to eyes without subclinical CNV.* A. 5.2 B. 10.2 C. 15.2 D. 20.2 10. The ForeseeHome by Notal Vision uses what technology to detect early and leaking choroidal neovascular membranes?* A. Sita Standard threshold perimetry B. Dark adaptation C. Preferential hyperacuity perimetry D. Optical coherent tomography 11. All of these are treatments for AMD, except?* A. Lifestyle changes with diet and exercise B. Systemic disease management C. Nutritional supplements D. Increase or encourage smoking 12. These biologic agents are used for the treatment for choroidal neovascularization (CNV), expect?* A. Bevacizumab (Avastin) B. Aflibercept (Eylea) C. Cenegermin-bkbj (Oxervate) D. Brolucizumab-dbll (Beovu) 13. What cornea condition occurs when the posterior cornea cone gets too steep and Descemet’s membrane ruptures?* A. Microcystic edema of the cornea B. Cornea hydrops C. Forme fruste keratoconus D. Cornea guttata 14. Cornea cross-linking procedure uses ultraviolet light and what molecule to stiffen and strengthen the cornea?* A. Lutein B. Riboflavin 5 C. Zeaxanthin D. Resveratrol 15. Amniotic Membranes are obtained:* A. At the time of birth, as the hospital can make money selling to amniotic membrane companies, patient unaware B. Are grown in a laboratory C. Are from planned Caesarean section births D. Are from placentas of humans and animals 16. An infectious cornea ulcer (bacterial or HSV keratitis) is diagnosed in your office. Which amniotic membrane is indicated?* A. Dehydrated amniotic membrane B. Cryopreserved amniotic membrane C. Both dehydrated and cryopreserved are indicated D. Both dehydrated and cryopreserved are contra-indicated 17. Which biologic drug is indicated for eye care and is the only one administrated as an eye drop?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 18. Which biologic drug is indicated for the treatment of neurotrophic keratitis?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 19. Which biologic drug is indicated for thyroid eye disease?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 20. Which of the following mechanisms most closely describes how Teprotumumab-trbw (Tepezza) works?* A. It binds to IGF-1 receptor and blocks its activation and signaling. B. It is an exact copy human nerve growth factor. C. It blocks vascular endothelial growth factor. D. It binds to TNF and blocks its action in the body. Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationHiddenRetake Code Interpretation and Utilization of New and Old Technologies | TQ Credit*After 4/20/2023, pricing will increase to $30. Price: (Past 60 Days) Interpretation and Utilization of New and Old Technologies | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: (Past 60 Days) Retake Discount Price: Payment MethodPayPal Checkout American ExpressDiscoverMasterCardVisaSupported Credit Cards: American Express, Discover, MasterCard, Visa Card Number Expiration Date Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
